...companies to make? And how would changes to that impact not just the number but the type of the drugs that they’re developing? I think that’s the more important question."
—Rachel Sachs, an attorney and law professor at Washington
University in St. Louis, spoke with AIS’s Radar on Drug Benefits about the odds
of drug pricing reform passing Congress before the midterm elections, and
whether new laws could stymie innovation.
No comments:
Post a Comment